ASCO: Rx Strategies Promising for CLL, Non-Hodgkin's Lymphoma

Share this content:
ASCO: Rx Strategies Promising for CLL, Non-Hodgkin's Lymphoma
ASCO: Rx Strategies Promising for CLL, Non-Hodgkin's Lymphoma

(HealthDay News) -- Two new targeted treatments have shown promise in slowing the progression of recurring chronic-lymphocytic leukemia (CLL) and slow-growing non-Hodgkin's lymphoma, researchers report. Both findings were to be reported Saturday at the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.

In one trial, ibrutinib appeared to greatly improve standard treatment for patients with recurring CLL. Ibrutinib (Imbruvica) reduced the risk of cancer progression or death by 80 percent when combined with bendamustine (Treanda) and rituximab (Rituxan), compared to the other two drugs being used on their own, the researchers found.

The ibrutinib trial involved 578 patients with recurring CLL. They were randomly assigned to receive either the usual two-drug treatment, or ibrutinib alongside the standard treatment. And while patients faced side effects from all three cancer drugs, the researchers found that no new side effects emerged from combining the medications.

Meanwhile, the obinutuzumab (Gazyva) clinical trial included 396 patients with various types of slow-growing non-Hodgkin's lymphoma. Obinutuzumab targets the CD20 protein, located on the surface of all B cells. According to previous research, when monoclonal antibodies attach to this protein, lymphoma cells either die or become more sensitive to chemotherapy. Patients were randomly assigned to receive just the chemotherapy drug bendamustine, or a combination of bendamustine and obinutuzumab. After an average follow-up of 21 months, progression-free survival was 14 months for bendamustine alone versus 29 months for the combination therapy, the investigators found.

The ibrutinib study received funding from Janssen Research & Development. The obinutuzumab study received funding from Genentech and Hoffmann-La Roche.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Dupilumab Reduces Rate of Severe Asthma Exacerbations

Dupilumab Reduces Rate of Severe Asthma Exacerbations

And, add-on dupilumab reduces glucocorticoid dose in patients with glucocorticoid-treated asthma

Better Social Support Network Protects Black Men Against HIV

Better Social Support Network Protects Black Men Against ...

Social networks of black men who have sex with men influence HIV risk behavior

Recommendations Developed for Managing Postpartum Pain

Recommendations Developed for Managing Postpartum Pain

Impact of medications on mother-infant dyad should be considered, as many women breastfeed

is free, fast, and customized just for you!

Already a member?

Sign In Now »